A. Barbier

1.3k total citations
39 papers, 1.0k citations indexed

About

A. Barbier is a scholar working on Oncology, Orthopedics and Sports Medicine and Molecular Biology. According to data from OpenAlex, A. Barbier has authored 39 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 14 papers in Orthopedics and Sports Medicine and 10 papers in Molecular Biology. Recurrent topics in A. Barbier's work include Bone health and treatments (16 papers), Bone health and osteoporosis research (14 papers) and Bone Metabolism and Diseases (8 papers). A. Barbier is often cited by papers focused on Bone health and treatments (16 papers), Bone health and osteoporosis research (14 papers) and Bone Metabolism and Diseases (8 papers). A. Barbier collaborates with scholars based in France, Japan and United States. A. Barbier's co-authors include Hiroshi Murakami, Toshio Suda, I. Nakamura, Nobuyuki Udagawa, Sakae Tanaka, N. Takahashi, Mitsuhiro Abe, Peer David, Roland Baron and T. Sasaki and has published in prestigious journals such as Journal of Controlled Release, Journal of Pharmacology and Experimental Therapeutics and Journal of Bone and Mineral Research.

In The Last Decade

A. Barbier

38 papers receiving 997 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
A. Barbier France 18 470 461 368 121 119 39 1.0k
Mohammad Shahnazari United States 21 323 0.7× 388 0.8× 600 1.6× 155 1.3× 92 0.8× 26 1.2k
Ana María Pino Chile 15 235 0.5× 350 0.8× 564 1.5× 135 1.1× 120 1.0× 49 1.4k
Dominique Egrise Belgium 18 171 0.4× 199 0.4× 280 0.8× 311 2.6× 83 0.7× 34 1.1k
Mikako Tanaka Japan 18 371 0.8× 362 0.8× 578 1.6× 62 0.5× 46 0.4× 39 1.1k
S. Viguet‐Carrin France 8 247 0.5× 590 1.3× 454 1.2× 181 1.5× 236 2.0× 8 1.2k
Sahar Mohsin United Arab Emirates 18 168 0.4× 246 0.5× 322 0.9× 173 1.4× 243 2.0× 41 1.1k
Mark S. Rybchyn Australia 20 407 0.9× 192 0.4× 552 1.5× 112 0.9× 126 1.1× 37 1.5k
Sergio Portal‐Núñez Spain 22 410 0.9× 240 0.5× 749 2.0× 163 1.3× 186 1.6× 45 1.4k
Satya S. Varanasi United Kingdom 10 148 0.3× 166 0.4× 388 1.1× 59 0.5× 117 1.0× 15 759
L V Avioli United States 10 253 0.5× 365 0.8× 481 1.3× 77 0.6× 51 0.4× 21 1.1k

Countries citing papers authored by A. Barbier

Since Specialization
Citations

This map shows the geographic impact of A. Barbier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Barbier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Barbier more than expected).

Fields of papers citing papers by A. Barbier

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Barbier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Barbier. The network helps show where A. Barbier may publish in the future.

Co-authorship network of co-authors of A. Barbier

This figure shows the co-authorship network connecting the top 25 collaborators of A. Barbier. A scholar is included among the top collaborators of A. Barbier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Barbier. A. Barbier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Dubois, Sandrine, et al.. (2016). Sélection et séquence optimale des éléments critiques de validation des ordonnances : une simulation avec des résidents en pharmacie hospitalière. Annales Pharmaceutiques Françaises. 75(2). 131–143. 3 indexed citations
2.
3.
Barbier, A.. (2004). Rôle de la pharmacologie in vivo en recherche et développement. Therapies. 59(1). 45–50. 1 indexed citations
4.
Barou, Odile, Valentin David, Laurence Vico, et al.. (2002). High-Resolution Three-Dimensional Micro-Computed Tomography Detects Bone Loss and Changes in Trabecular Architecture Early. Investigative Radiology. 37(1). 40–46. 78 indexed citations
5.
Barbier, A., et al.. (2002). [Regulatory status of safety pharmacology. Implications].. PubMed. 57(2). 104–8. 2 indexed citations
6.
Lacheretz, F., et al.. (2000). Effect of SR121463, a Selective Non-Peptide Vasopressin V 2 Receptor Antagonist, in a Rabbit Model of Ocular Hypertension. Journal of Ocular Pharmacology and Therapeutics. 16(3). 203–216. 17 indexed citations
7.
Filmon, R., M.F. Baslé, A. Barbier, & Daniel Chappard. (2000). Poly(2-hydroxy ethyl methacrylate)-alkaline phosphatase: A composite biomaterial allowing in vitro studies of bisphosphonates on the mineralization process. Journal of Biomaterials Science Polymer Edition. 11(8). 849–868. 42 indexed citations
8.
Rohanizadeh, Ramin, Racquel Z. LeGeros, Sylvain Bohic, et al.. (2000). Ultrastructural Properties of Bone Mineral of Control and Tiludronate-Treated Osteoporotic Rat. Calcified Tissue International. 67(4). 330–336. 23 indexed citations
9.
Bohic, Sylvain, Christian Rey, A.P. Legrand, et al.. (2000). Characterization of the trabecular rat bone mineral: effect of ovariectomy and bisphosphonate treatment. Bone. 26(4). 341–348. 65 indexed citations
10.
Barbier, A., Catherine Martel, M.C. de Vernejoul, et al.. (1999). The visualization and evaluation of bone architecture in the rat using three-dimensional X-Ray microcomputed tomography. Journal of Bone and Mineral Metabolism. 17(1). 37–44. 59 indexed citations
11.
Carayon, P, et al.. (1999). Contact allergens, but not irritants, alter receptor-mediated endocytosis by human epidermal Langerhans cells. British Journal of Dermatology. 140(2). 200–209. 18 indexed citations
12.
Murakami, Hiroshi, N. Takahashi, Sakae Tanaka, et al.. (1997). Tiludronate inhibits protein tyrosine phosphatase activity in osteoclasts. Bone. 20(5). 399–404. 59 indexed citations
13.
Ohnishi, Hideo, Tetsuya Nakamura, Kenichiro Narusawa, et al.. (1997). Bisphosphonate tiludronate increases bone strength by improving mass and structure in established osteopenia after ovariectomy in rats. Bone. 21(4). 335–343. 49 indexed citations
14.
Nasraoui, B., A. Barbier, & Philippe Lepoivre. (1996). Effect of three antitranspirant films on Botrytis cinerea activities in vitro. Arab Journal Of Plant Protection. 1 indexed citations
15.
Laroche, Michel, et al.. (1996). Effect of ovariectomy on intraosseous vascularization and bone remodelling in rats: Action of tiludronate. Osteoporosis International. 6(2). 127–129. 9 indexed citations
16.
Murakami, Hiroshi, N. Takahashi, T. Sasaki, et al.. (1995). A possible mechanism of the specific action of bisphosphonates on osteoclasts: Tiludronate preferentially affects polarized osteoclasts having ruffled borders. Bone. 17(2). 137–144. 173 indexed citations
17.
Bonjour, JP, Patrick Ammann, A. Barbier, Joseph Caverzasio, & René Rizzoli. (1995). Tiludronate: Bone pharmacology and safety. Bone. 17(5). S473–S477. 19 indexed citations
18.
Geusens, Piet, Jo Nijs, Georges Van der Perre, et al.. (1992). Longitudinal effect of tiludronate on bone mineral density, resonant frequency, and strength in monkeys. Journal of Bone and Mineral Research. 7(6). 599–609. 39 indexed citations
19.
Barbier, A., et al.. (1984). Biochemical and clinical changes in rats with developing adjuvant arthritis. Inflammation Research. 15(1-2). 103–105. 14 indexed citations
20.
Girard, J., et al.. (1982). Etude expérimental de l'indice de protection de produits antisolaires. Valeur prédictive à l'homme. International Journal of Cosmetic Science. 4(4). 115–132. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mohammad Shahnazari Breakdown of academic impact, for papers by Ana María Pino Breakdown of academic impact, for papers by Dominique Egrise Breakdown of academic impact, for papers by Mikako Tanaka Breakdown of academic impact, for papers by S. Viguet‐Carrin Breakdown of academic impact, for papers by Sahar Mohsin Breakdown of academic impact, for papers by Mark S. Rybchyn Breakdown of academic impact, for papers by Sergio Portal‐Núñez Breakdown of academic impact, for papers by Satya S. Varanasi Breakdown of academic impact, for papers by L V Avioli
Rankless by CCL
2026